Success of continuous veno-venous hemodiafiltration treatment in children monitored in the intensive care units

Figures & data

Figure 1. Distribution of diagnoses in non-cardiac cases. Note: AKF, acute kidney failure; CKF, chronic kidney failure; ALL, acute lymphoblastic leukemia.

Figure 2. Primary and secondary survival rates for cardiac and non-cardiac cases.

Figure 3. Consultation and CVVHDF time according to primary and secondary survival status. Notes: *Group 1: Primary survival – yes, secondary survival – yes. **Group 2: Primary survival – yes, secondary survival – no. ***Group 3: Primary survival – no, secondary survival –yes. ****Group 4: Primary survival – no, secondary survival – no.

Table 1. Consultations.

Groups	Difference in means	Standard error	%95 Confidence interval
2 versus 1	4.44	2.73	−2.956177 to 11.8315
3 versus 1	−3.84	3.95	−14.5556 to 6.873782
4 versus 1	−0.88	3.27	−9.749231 to 7.995984
3 versus 2	−8.28	3.84	−18.68263 to 2.125483
4 versus 2	−5.31	3.14	−13.80916 to 3.180589
4 versus 3	2.96	4.25	−8.537829 to 14.4664

Table 2. Timing of CVVHDF initiation.

Group	Difference in means	Standard error	%95 Confidence interval
2 versus 1	−0.0454545	0.4471106	−1.256839 to 1.16593
3 versus 1	−0.7954545	0.6479248	−2.550917 to 0.9600081
4 versus 1	−0.3311688	0.5365327	−1.78483 to 1.122492
3 versus 2	−0.75	0.6291404	−2.454569 to 0.9545688
4 versus 2	−0.2857143	0.513691	−1.677489 to 1.10606
4 versus 3	0.4642857	0.6955409	−1.420186 to 2.348757

Table 3. CVVHDF duration.

Groups	Difference in means	Standard error	%95 Confidence interval
2 versus 1	32.31169	20.52467	−23.29706 to 87.92043
3 versus 1	−22.04545	29.74307	−102.6302 to 58.53927
4 versus 1	−35.97403	24.6296	−102.7045 to 30.75647
3 versus 2	−54.35714	28.88077	−132.6056 to 23.8913
4 versus 2	−68.28571	23.58105	−132.1753 to −4.39613
4 versus 3	−13.92857	31.92889	−100.4355 to 72.57833